Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S is a biotechnology firm focused on the discovery, development, and commercialization of peptide-based medications. The company's therapeutic pipeline and marketed products primarily address gastrointestinal and metabolic diseases, as well as other niche conditions with significant unmet medical needs. Currently, Zealand Pharma markets lixisenatide under the brand names Adlyxin and Lyxumia. Its product portfolio also includes Dasiglucagon, offered as a single-use syringe or autoinjector for managing severe hypoglycemia, congenital hyperinsulinism, and post-bariatric surgery hypoglycemia, alongside its use in a dual-hormone artificial pancreas for automated diabetes care. In its advanced development stage, Dasiglucagon is progressing through Phase III clinical trials for congenital hyperinsulinism. Another significant late-stage asset is glepaglutide, a long-acting GLP-2 analogue, also in Phase III trials for the treatment of short bowel syndrome. Zealand Pharma A/S has established key collaboration agreements with entities such as Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.


Net sales
Gross margin
Net income